Smallpox vaccine: Problems and prospects

Gregory A. Poland, John M. Neff

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Smallpox justifiably is feared because of its morbidity and mortality. Widespread population-level susceptibility to smallpox exists, and the only effective tool against the virus is a live, attenuated vaccine that is highly reactogenic and controversial. A significant minority of the population has contraindications that prevent preexposure use of this vaccine. Newer, safer, and equally immunogenic vaccines must be developed and licensed. Several live, attenuated vaccines are in clinical trials. Although these vaccines may prove to be less reactogenic, they still may not be administered safely to a significant portion of the population because they contain live, attenuated viruses. Newer vaccines will be needed if routine preexposure vaccination is to be instituted universally. The idea of a subunit or peptide-based vaccine is appealing, because it obviates potential safety concerns. It may be possible to use a more-attenuated, live vaccine strain for a large segment of the population on a preexposure basis and accept the morbidity and mortality that would result from its use on a postexposure basis, if necessary. The need for widespread population-level protection against variola infection is apparent. The use of the new biology tools to predict or define who might experience serious reactions to the smallpox vaccine and why these reactions occur is an area ripe for additional research. The reason why an individual develops postvaccinal encephalitis remains unknown, and the development is unpredictable and untreatable. In the future, if the mechanism behind such adverse events is defined, it may be possible to screen persons who are likely to experience such events. Although the authors remain proponents for use of the vaccine in alignment with the CDC vaccination program and recommendations, the previous concerns indicate that new knowledge must be gained and shared. Further research on attenuated vaccines and nonliving or peptide vaccines with equal efficacy should remain the goal, as it is apparent that smallpox vaccine once again will become part of the vaccinologist's and public health official's armamentarium in the decades to come.

Original languageEnglish (US)
Pages (from-to)731-743
Number of pages13
JournalImmunology and Allergy Clinics of North America
Volume23
Issue number4
DOIs
StatePublished - Nov 2003

Fingerprint

Smallpox Vaccine
Attenuated Vaccines
Vaccines
Smallpox
Subunit Vaccines
Population
Vaccination
Acute Disseminated Encephalomyelitis
Viruses
Morbidity
Mortality
Centers for Disease Control and Prevention (U.S.)
Research
Public Health
Clinical Trials
Safety
Infection

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Smallpox vaccine : Problems and prospects. / Poland, Gregory A.; Neff, John M.

In: Immunology and Allergy Clinics of North America, Vol. 23, No. 4, 11.2003, p. 731-743.

Research output: Contribution to journalArticle

Poland, Gregory A. ; Neff, John M. / Smallpox vaccine : Problems and prospects. In: Immunology and Allergy Clinics of North America. 2003 ; Vol. 23, No. 4. pp. 731-743.
@article{8950561951f3448e9b695c3214cbb346,
title = "Smallpox vaccine: Problems and prospects",
abstract = "Smallpox justifiably is feared because of its morbidity and mortality. Widespread population-level susceptibility to smallpox exists, and the only effective tool against the virus is a live, attenuated vaccine that is highly reactogenic and controversial. A significant minority of the population has contraindications that prevent preexposure use of this vaccine. Newer, safer, and equally immunogenic vaccines must be developed and licensed. Several live, attenuated vaccines are in clinical trials. Although these vaccines may prove to be less reactogenic, they still may not be administered safely to a significant portion of the population because they contain live, attenuated viruses. Newer vaccines will be needed if routine preexposure vaccination is to be instituted universally. The idea of a subunit or peptide-based vaccine is appealing, because it obviates potential safety concerns. It may be possible to use a more-attenuated, live vaccine strain for a large segment of the population on a preexposure basis and accept the morbidity and mortality that would result from its use on a postexposure basis, if necessary. The need for widespread population-level protection against variola infection is apparent. The use of the new biology tools to predict or define who might experience serious reactions to the smallpox vaccine and why these reactions occur is an area ripe for additional research. The reason why an individual develops postvaccinal encephalitis remains unknown, and the development is unpredictable and untreatable. In the future, if the mechanism behind such adverse events is defined, it may be possible to screen persons who are likely to experience such events. Although the authors remain proponents for use of the vaccine in alignment with the CDC vaccination program and recommendations, the previous concerns indicate that new knowledge must be gained and shared. Further research on attenuated vaccines and nonliving or peptide vaccines with equal efficacy should remain the goal, as it is apparent that smallpox vaccine once again will become part of the vaccinologist's and public health official's armamentarium in the decades to come.",
author = "Poland, {Gregory A.} and Neff, {John M.}",
year = "2003",
month = "11",
doi = "10.1016/S0889-8561(03)00096-1",
language = "English (US)",
volume = "23",
pages = "731--743",
journal = "Immunology and Allergy Clinics of North America",
issn = "0889-8561",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Smallpox vaccine

T2 - Problems and prospects

AU - Poland, Gregory A.

AU - Neff, John M.

PY - 2003/11

Y1 - 2003/11

N2 - Smallpox justifiably is feared because of its morbidity and mortality. Widespread population-level susceptibility to smallpox exists, and the only effective tool against the virus is a live, attenuated vaccine that is highly reactogenic and controversial. A significant minority of the population has contraindications that prevent preexposure use of this vaccine. Newer, safer, and equally immunogenic vaccines must be developed and licensed. Several live, attenuated vaccines are in clinical trials. Although these vaccines may prove to be less reactogenic, they still may not be administered safely to a significant portion of the population because they contain live, attenuated viruses. Newer vaccines will be needed if routine preexposure vaccination is to be instituted universally. The idea of a subunit or peptide-based vaccine is appealing, because it obviates potential safety concerns. It may be possible to use a more-attenuated, live vaccine strain for a large segment of the population on a preexposure basis and accept the morbidity and mortality that would result from its use on a postexposure basis, if necessary. The need for widespread population-level protection against variola infection is apparent. The use of the new biology tools to predict or define who might experience serious reactions to the smallpox vaccine and why these reactions occur is an area ripe for additional research. The reason why an individual develops postvaccinal encephalitis remains unknown, and the development is unpredictable and untreatable. In the future, if the mechanism behind such adverse events is defined, it may be possible to screen persons who are likely to experience such events. Although the authors remain proponents for use of the vaccine in alignment with the CDC vaccination program and recommendations, the previous concerns indicate that new knowledge must be gained and shared. Further research on attenuated vaccines and nonliving or peptide vaccines with equal efficacy should remain the goal, as it is apparent that smallpox vaccine once again will become part of the vaccinologist's and public health official's armamentarium in the decades to come.

AB - Smallpox justifiably is feared because of its morbidity and mortality. Widespread population-level susceptibility to smallpox exists, and the only effective tool against the virus is a live, attenuated vaccine that is highly reactogenic and controversial. A significant minority of the population has contraindications that prevent preexposure use of this vaccine. Newer, safer, and equally immunogenic vaccines must be developed and licensed. Several live, attenuated vaccines are in clinical trials. Although these vaccines may prove to be less reactogenic, they still may not be administered safely to a significant portion of the population because they contain live, attenuated viruses. Newer vaccines will be needed if routine preexposure vaccination is to be instituted universally. The idea of a subunit or peptide-based vaccine is appealing, because it obviates potential safety concerns. It may be possible to use a more-attenuated, live vaccine strain for a large segment of the population on a preexposure basis and accept the morbidity and mortality that would result from its use on a postexposure basis, if necessary. The need for widespread population-level protection against variola infection is apparent. The use of the new biology tools to predict or define who might experience serious reactions to the smallpox vaccine and why these reactions occur is an area ripe for additional research. The reason why an individual develops postvaccinal encephalitis remains unknown, and the development is unpredictable and untreatable. In the future, if the mechanism behind such adverse events is defined, it may be possible to screen persons who are likely to experience such events. Although the authors remain proponents for use of the vaccine in alignment with the CDC vaccination program and recommendations, the previous concerns indicate that new knowledge must be gained and shared. Further research on attenuated vaccines and nonliving or peptide vaccines with equal efficacy should remain the goal, as it is apparent that smallpox vaccine once again will become part of the vaccinologist's and public health official's armamentarium in the decades to come.

UR - http://www.scopus.com/inward/record.url?scp=0346965789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346965789&partnerID=8YFLogxK

U2 - 10.1016/S0889-8561(03)00096-1

DO - 10.1016/S0889-8561(03)00096-1

M3 - Article

C2 - 14753389

AN - SCOPUS:0346965789

VL - 23

SP - 731

EP - 743

JO - Immunology and Allergy Clinics of North America

JF - Immunology and Allergy Clinics of North America

SN - 0889-8561

IS - 4

ER -